Clinical trials: psoriasis
Moderate Plaque Psoriasis
A Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)
For patients with moderate plaque psoriasis who are intolerable to, have a contraindication to or have failed classical systemic treatments, the current commonly employed management strategy encompasses treatment with biologic…
- Trial name
- APRAISAL (NCT03059953)
- Where
- Greece
- Volunteers
- 302 people
- Sponsor
- Genesis Pharma S.A.
Psoriatic Arthritis
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)
- Trial name
- NCT00051662
- Testing
- efalizumab
- Volunteers
- 45 people
- Sponsor
- XOMA (US) LLC
Psoriasis
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.
- Trial name
- NCT07150988
- Testing
- HSK44459 dose level 1, HSK44459 dose level 2
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Psoriasis
Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept
This study proposes to compare 2 different methods for managing a subject with psoriasis who has achieved good disease control, as defined by a clinical response with a Physician Global Assessment (PGA) inferior or equal to 1 at…
- Trial name
- ReSPONSE (NCT00992394)
- Testing
- etanercept
- Where
- 46 sites in France, Germany and 7 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Psoriasis
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.
- Trial name
- NCT00230529
- Testing
- infliximab
- Volunteers
- 249 people
- Sponsor
- Centocor, Inc.
Psoriatic Arthritis
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
- Trial name
- NCT05511519
- Testing
- ATI-450
- Where
- 22 sites in United States, Poland
- Volunteers
- 47 people
- Sponsor
- Aclaris Therapeutics, Inc.
Psoriasis Vulgaris
Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris
A Phase 2 Maximal Use Systemic Exposure (MUSE) study evaluating the safety and efficacy of LEO 90100 used once daily in subjects with extensive psoriasis vulgaris.
- Trial name
- NCT01600222
- Testing
- LEO 90100
- Where
- 10 sites in Canada
- Volunteers
- 37 people
- Sponsor
- LEO Pharma
Psoriasis
Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults
BFI-751 is being developed by BioFactura Australia Pty Ltd as a biosimilar drug to Stelara® (EU licenced and US licenced) (ustekinumab) is a prescription biologic medicine used to treat people with Crohn's disease, Ulcerative…
- Trial name
- NCT04843631
- Testing
- BFI-751, EU-STELARA®, US-STELARA®
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- BioFactura Australia Pty Ltd.
Psoriasis
Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis
Dithranol (known in the U.S.A. as anthralin and in Germany as cignolin) is one of the oldest and safest topical anti-psoriatic treatments.
- Trial name
- NCT02752672
- Where
- Austria
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Psoriasis Vulgaris
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months…
- Trial name
- NCT02125279
- Testing
- Calcitriol
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 54 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
- Trial name
- NCT03210961
- Testing
- PF-06826647 tablet, PF-06826647 oral suspension
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nail Psoriasis, Plaque Psoriasis
Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis
Part 1 is a randomized, double-blind, placebo-controlled phase 1b study to evaluate AT193 in approximately 34 patients with nail psoriasis for 16 weeks.
- Trial name
- NCT05072886
- Testing
- AT193
- Where
- Australia
- Volunteers
- 34 people
- Sponsor
- Azora Therapeutics Australia Pty Ltd
Chronic Plaque Psoriasis
Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis
It is a phase IV multicentric, placebo-controlled, clinical trial investigating the efficacy and safety of acitretin combined to efalizumab in the therapy of chronic plaque psoriasis.
- Trial name
- CobAcE (NCT00707070)
- Testing
- efalizumab plus acitretin
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universita di Verona
Psoriatic Arthritis
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3…
- Trial name
- INVIGORATE 2 (NCT04209205)
- Testing
- AIN457 6 mg/kg i.v., AIN457 3 mg/kg
- Where
- 80 sites in United States, Brazil and 13 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)
This Phase 2 study (Study 203) has been designed to determine and compare the efficacy and safety of 188-0551 Solution and Vehicle Solution applied twice daily for up to four weeks in subjects with plaque psoriasis.
- Trial name
- NCT03065556
- Testing
- 188-0551 Solution, Vehicle Solution
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Therapeutics, Inc.
Psoriasis
Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis
In this study, the investigators will intend to compare the efficacy and safety of various doses of acitretin in a randomized double blind manner in patients with severe plaque-type psoriasis, by i) studying the change PASI score…
- Trial name
- NCT01039142
- Testing
- Acitretin
- Where
- India
- Volunteers
- 61 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Plaque Psoriasis
Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, positive drug parallel-group controlled clinical study in China to evaluate efficacy, safety, tolerability and immunogenicity of HLX03 and adalimumab (Humira) in subjects with…
- Trial name
- NCT03316781
- Testing
- HLX03, adalimumab
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Shanghai Henlius Biotech
Psoriasis, Psoriasis Vulgaris
Iontophoresis in Psoriasis
Iontophoresis potentially may be a good alternative to improved delivery of corticosteroids. Study Investigators propose to use iontophoresis to increase dexamethasone delivery into thick psoriasis plaques.
- Conditions
- Psoriasis, Psoriasis Vulgaris, Skin Diseases
- Trial name
- NCT03979664
- Testing
- Activapatch intellidose 2.5 using active Iontophoresis, Activapatch intellidose 2.5 using inactive Iontophoresis, Dexamethasone
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Asthma
The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance
This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance.
- Trial name
- NCT06224634
- Where
- Denmark
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Hvidovre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.